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Abstract
Background
Truncated tau appears to be specifically related to disease pathology and recent studies
have shown the presence and elevation of several truncated tau species in Cerebrospinal
fluid (CSF) of subjects with Alzheimer’s disease (AD); however, the relevance of truncated
Tau measurements in blood is still being studied.
Objective
The aim of the current study was to assess the longitudinal associations between baseline
levels of two novel blood biomarker candidates measuring truncated tau, Tau-A and Tau-C,
and the risk of incident dementia and AD in elderly women.
Methods
Using solid phase competitive ELISA, two tau fragments were detected in serum of 5,309
women from the Prospective Epidemiological Risk Factor study. The study was an observa-
tional, prospective study of Danish postmenopausal women. Subjects were followed with
registry-linkage for up to 15 years (median follow-up time 13.7 years). Cox regression was
used to assess the utility of the biomarker candidates in relation to dementia and AD.
Results
High levels of Tau-A and Tau-C (above the median) in blood were associated with lower risk
of dementia and AD (Tau-A: Dementia HR[95% CI] = 0.85[0.70–1.04]; AD 0.71[0.52–0.98]
and Tau-C: Dementia 0.84[0.70–1.00]; AD 0.78[0.60–1.03]). Tau-C gave a very modest
increase in the AUC in a 5-year prediction horizon as compared to a reference model with
age and education, while a combination of the two did not improve their predictive capacity.
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Conclusions
Measurement of tau in serum is feasible. The serological tau turnover profile may be related
to the diagnosis and development of dementia and AD. The exact processing and profile in
serum in relation to cognitive disorders remains to be further assessed to provide simple
non-invasive tests to identify subjects with progressive cognitive disorders.
Introduction
The global burden of dementia is rising, with a new case registered every 3.2 seconds. Demen-
tia is ranked as the 9th most burdensome disease for people aged 60 years and older, however
the costs associated with dementia are enormous and place dementia as the most expensive
disease in the United States. The reason for this increase in dementia prevalence and the fol-
lowing increased costs are mainly caused by the shifting epidemiological trend of increasing
numbers of elder people, caused by low fertility rates and increasing longevity [1,2].
To counteract this dreary trend there is a need for better treatments. The success in phar-
maceutical drug development has been greatly challenged due to the difficulties in detecting
the disease at a stage allowing for intervention and thereby detecting efficacy. Consequently,
there is a clear need for non-invasive and reliable biomarkers to aid in early diagnosis, progno-
sis and early efficacy assessment. Cerebrospinal fluid (CSF) biomarkers exist, and while they
aid in diagnosis, their clinical utility is limited due to the invasive nature of the lumbar
puncture.
Evidence suggests that tau is possibly the protein triggering and driving the process of
cognitive decline and neuronal loss in Alzheimer’s disease (AD)[3,4]. Besides AD, tau is
known to be involved in the pathogenesis of several other dementias. The common
denominator for these diseases is an alteration of the tau protein leading to the generation
of neurotoxic tau species, i.e. neurofibrillary tangles (NFTs) in AD[5]. During this process
the tau protein is known to undergo several different posttranslational modifications,
where phosphorylation is among the most well studied. Several studies indicate that pro-
teolytic processing of tau plays an important role in neurodegeneration and it has been
suggested that caspase cleavage of tau may precede the hyper-phosphorylation, where
especially caspase cleavage at Asp421 has been shown to initiate the cascade leading to tau
aggregation[6–8].
Recently our research group developed two solid phase competitive ELISA assays detecting
the caspase-generated fragment cleaved at Asp421 (Tau-C) and another detecting an
ADAM10-generated fragment cleaved at Ala152 (Tau-A) of tau. These novel biomarker candi-
dates have shown promising results in the initial biological validation: In ice hockey players
suffering from mild traumatic brain injury, serum levels of Tau-C were significantly higher in
post-concussion samples compared with preseason samples[9], confirming that tau processing
and release into the circulation is associated with brain damage. Further, levels of Tau-A corre-
lated with the duration of post-concussive symptoms, clearly indicating relevance to the neu-
ronal damage[9]. In a smaller dementia cohort the tau fragments have been shown to be able
to discriminate between AD and Mild Cognitive Impairment (MCI) which shows that the tau
fragments can provide guidance on the differential diagnosis of dementia[10].
The aim of the current study was to assess the longitudinal associations between baseline
levels of Tau-A and Tau-C in serum and the risk of incident dementia and Alzheimer’s disease
in a large prospective cohort of 5,309 elderly women.
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Materials and methods
Study population
The Prospective Epidemiological Risk Factor (PERF) study was an observational, prospective
study of Danish postmenopausal women. The cohort has been described in details elsewhere
[11]. A total of 5,855 women aged 55–85 were enrolled in the study. Being woman and post-
menopausal were the only inclusion criteria’s at the time of enrolment. The baseline examina-
tion took place between 1999 and 2001 and comprised a questionnaire, physical examination
and blood sampling at the study site. The study was carried out in accordance with ICH-GCP
with study protocol approval from The Research Ethics Committee of Copenhagen County.
Written informed consent was obtained from all subjects prior to any study related procedures.
Of the entire baseline population (n = 5,855), a total of 206 subjects were excluded based on
their cognitive performance at baseline, indicating cognitive impairment consistent with
dementia (a Short Blessed Test score10). Two hundred fifty-three subjects did not complete
the cognitive testing at baseline and were also excluded in the current study. In addition, 12
subjects were excluded from the analysis due to a preexisting dementia diagnosis derived from
the National Danish Patient Registry prior to study enrolment. Further 75 subjects were
excluded since no serum samples was available for biomarker measurement. The analytical
sample in the current study therefore constituted 5,309 subjects.
ELISA methodology
The neo-epitope fragments of tau were detected using solid phase competitive ELISA. Frag-
ments were detected by mouse monoclonal antibodies raised against human tau. The antibod-
ies detect an ADAM10-generated cleavage site at Ala152 (Tau-A) and the caspase-3-generated
cleavage site at Asp421 (Tau-C). The monoclonal antibodies recognize a decamer sequence
containing the cleavage site. Both assays have previously been described in details elsewhere
[12,13]. The lower limit of quantification (LLOQ) for Tau-A was 29.4 ng/ml. For Tau-A 68%
(n = 3,595) of samples were below the LLOQ. If their reported value were above the lower
limit of detection (LLOD, n = 3,443) and their respective Intra-Assay Coefficients of Variabil-
ity (CV) allowed for it (<15%) these samples were assigned their absolute value (n = 2,293)
(see S1 Fig for flow chart on sample inclusion/exclusion). In total 1,150 samples in the range
between LLOQ and LLOD were excluded from the main analysis due to an Intra-Assay
CV 15%. A sensitivity analysis including these samples was performed as outlined in the sta-
tistical analysis section. The LLOD was 9.3 ng/ml. Samples measured below the LLOD were
assigned the LLOD value (n = 152). The LLOQ for Tau-C was determined as 8.6 ng/ml. For
Tau-C, samples measured below the LLOQ were assigned the LLOQ value (n = 139). The
LLOD for Tau-C was 0.8 ng/ml.
To avoid confounding from plate to plate variation, a series of QC samples were run on 25
plates to provide the range of these measurements with variation. These controls were then
included on all plates during the analytical run, and only plates fulfilling the criterion of less
than 20% variation from the original validation data set are accepted as valid, and alternatively
rerun if this value was too high. The biomarker analysis were conducted at a College of Ameri-
can Pathology (CAP) certified central laboratory (Nordic Bioscience Laboratory). The staff at
the central laboratory had no knowledge of the study participants.
Dementia diagnosis
Follow-up information on dementia status was retrieved from the National Danish Patient
Registry and the National Danish Causes of Death Registry using a unique personal
Serum biomarker candidates are associated with dementia
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identification number for each subject. The follow-up started on the day of study enrollment
and ended at the occurrence of an event (dementia diagnosis), death, or on the day of the
retrieval of registry data (December 31th 2014), whichever came first. A total of 538 incident
dementia cases were identified from the registries. Dementia diagnoses were classified accord-
ing to The International Classification of Diseases, 10 th revision (ICD10). The following codes
were considered a dementia diagnosis: F00-F04, G30-G32 and R54, while F00 and G30 was
used to identify AD (n = 232); however, the registries do not grant access to the data support-
ing the diagnoses.
Statistical analysis
Statistical analysis was conducted using R version 3.3.1 (R Foundation for Statistical Comput-
ing, Vienna, Austria). Serum levels of Tau-A and Tau-C were log-transformed to account for
the skewness and then z-score standardized using the population mean and standard deviation
(SD). In cause-specific Cox proportional hazards regression models, all-cause dementia and
Alzheimer’s disease were used as the dependent variables. Age was used as timescale and event-
free mortality was included as a competing risk as outlined by Benichou and Gail[14]. Levels of
the tau fragments were included as either a continuous variable to reflect the risk associated
with a change of one SD on the log scale, or as a categorical variable either dichotomized at the
median (the group below the median was used as reference) or divided into quartiles (the lowest
quartile (Q1) was used as reference). Initially we modeled the crude risk in the separate univari-
ate analysis (model 1). Secondly, in addition to age, we adjusted for education level (primary
school, high school and university) (model 2). Lastly we made a multivariate model adjusted for
the continuous variables; age (as timescale), body mass index (kg/m2), platelet count (109/L),
white blood cell count (109/L), albumin (mmol/L), alkaline phosphatase (unit/L), gamma gluta-
myltransferase (unit/L), high-density lipoprotein (mmol/L) and the categorical variables; educa-
tion level, smoking (never, past or current), alcohol consumption (never,<10.5 alcohol units/
week, 10.5–21 alcohol units/week or>21 alcohol units/week), physical activity (other than
walking) (never, once weekly, twice weekly or three or more times per week) (model 3). Selec-
tion of covariates was based on significant association with levels of Tau-A and Tau-C using a
multiple linear regression analysis (data not shown) and relevant risk factors as reported in the
literature. A sensitivity analysis was performed for Tau-A by including all samples between
LLOQ and LLOD with an intra-assay CVs above the initial requirement of<15%.
The cumulative incidence of a dementia event in a competing risk framework taking the
risk of death without dementia into account was illustrated in quartiles of Tau-A and Tau-C.
The cumulative incidence was estimated using the Aalen–Johansen method[15]. The differ-
ence between cumulative incidence curves was tested using the modified χ2 statistic outlined
by Gray[16].
Finally we investigated the predictive value of the two biomarker candidates when added i)
to a reference model containing age and educational level and ii) to a reference model contain-
ing all the independent variables from the multivariate model. The predictive value was
assessed by computing the area under the Receiver-Operating Characteristics curve (AUC) for
a 5-year and 10-year prediction horizon for each of the individual markers and their combina-
tion, using time from baseline as timescale.
Results
Selected baseline characteristics of the study population are summarized in Table 1. During
the follow-up period of maximum 15 years (median follow-up time 13.7 years) a total of 538
incident dementia cases were identified from the registries, of which 232 had AD.
Serum biomarker candidates are associated with dementia
PLOS ONE | https://doi.org/10.1371/journal.pone.0194802 April 11, 2018 4 / 13
Cause-specific Cox proportional hazards regression models were used to assess the associa-
tion between the biomarker levels and the risk of incident dementia or AD as listed in Table 2.
Higher levels of Tau-C, both as a continuous measure and categorized, were associated with a
decreased risk of all-cause dementia and AD in the age-adjusted model. Subjects in the highest
quartile had a 29% (HR [95% CI] 0.71 [0.55–0.91]) decreased risk of dementia and a 34% (HR
[95% CI] 0.66 [0.46–0.96]) decreased risk of AD as compared to subjects within the lowest
quartile. A dose-response tendency was observed for Tau-C in all three models, indicating
decreasing risk of dementia with increasing levels of the biomarker.
The association between Tau-C and incident dementia and AD remained significant after
adjustment for age and education and in the multi adjusted model. Tau-C levels in the highest
quartile were associated with a 29% lower risk of dementia and 34% lower risk of AD, when
adjusted for age and education. In the multi adjusted model, subjects in the highest quartile
had a 24% (HR [95% CI] 0.76 [0.58–0.98]) lower risk of dementia as compared to subjects in
the lowest quartile. Further, the risk of dementia and AD decreased 10% (HR [95% CI] 0.90
[0.82–0.99]) and 13% (HR [95% CI] 0.87 [0.75–1.00]) with every log SD increase of the bio-
marker, respectively.
A dose-response relation was also observed with across the quartiles of Tau-A, and as con-
tinuous measure the risk decreased 13% (HR [95% CI] 0.87 [0.79–0.96]) in relation to all-
cause dementia and 17% (HR [95% CI] 0.83 [0.72–0.96]) in relation to AD with every log SD
Table 1. Study population characteristics at baseline. Numbers are shown as absolute numbers with percentile in
brackets for categorical variables. For numerical variables, the mean (standard deviation) is shown.
Parameter Dementia (n = 538) Controls (n = 4771)
Age, mean (SD) (years) 70.0 (6.4) 75.1 (5.4)
Highest level of education
Primary school, n (%) 386 (72) 3357 (70)
High School, n (%) 107 (20) 1061 (22)
University, n (%) 44 (8) 347 (7)
BMI, mean (SD) (kg/m2) 26.2 (4.2) 25.8 (4.2)
Smoking
Never, n (%) 260 (48) 2272 (48)
Past, n (%) 180 (33) 1428 (30)
Current, n (%) 98 (18) 1067 (22)
Alcohol
Never, n (%) 250 (47) 2012 (42)
<10.5 units/week, n (%) 126 (24) 1126 (24)
10.5–21 units/week, n (%) 128 (24) 1256 (27)
>21 units/week, n (%) 32 (6) 341 (7)
Physical activity
Never, n (%) 195 (36) 1398 (29)
1 time/week, n (%) 112 (21) 1015 (21)
2 times/week, n (%) 70 (13) 632 (13)
3+ times/week, n (%) 159 (30) 1722 (36)
Hypertension, n (%) 182 (34) 1435 (30)
History of stroke, n (%) 24 (4) 133 (3)
Diabetes, n (%) 11 (2) 135 (3)
Depression/Anxiety, n(%) 50 (9) 295 (6)
Tau-A level, mean (SD) (ng/mL) 28.3 (16.0) 26.8 (14.5)
Tau-C level, mean (SD) (ng/mL) 22.0 (11.9) 20.3 (10.4)
https://doi.org/10.1371/journal.pone.0194802.t001
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increase of the biomarker in the age and educationally adjusted model, respectively. When
dichotomized at the median subjects above the median had a 19% lower risk of dementia (HR
[95% CI] 0.81 [0.67–0.98]) and a 32% lower risk of AD (HR [95% CI] 0.68 [0.50–0.91]). After
multi factor adjustment the association between Tau-A and incident dementia and AD van-
ished, however the association remained significant between Tau-A and all-cause dementia as
a continuous measure and in the dichotomized analysis, where subjects above the median had
29% decreased risk of AD (HR [95% CI] 0.71 [0.52–0.98]). The sensitivity analysis for Tau-A
did not alter the overall results. Thus, there was a minor tendency for both outcomes where
the HRs was shifted modestly towards the null (data not shown).
The two tau biomarker candidates were also stratified into quartiles and illustrated as
cumulative incidence curves (Fig 1).
The analysis showed that the separation between Q1 and Q4 for Tau-A in relation to all-
cause dementia is poor, and with significant overlap between confidence intervals for Q1 and
Q4 (Fig 1A, p = 0.2). For AD on the other hand, the separation between Q1 and Q4 is larger
(Fig 1D, p = 0.03). For Tau-C, the separation between the quartiles is larger and with only
minor overlap between the confidence limits of Q1 and Q4 (Fig 1B, E, p = 0.0009 for dementia
and p = 0.01 for AD). Moreover, a dose-response relation across the four quartiles is observed
for Tau-C in relation to both dementia and AD. The overlay plots (Fig 1C and 1F) illustrate
Q1 and Q4 for both biomarkers. It appears that the distance and thereby the separation
between Q1 and Q4 increases from Tau-A to Tau-C.
As outlined in Table 3, Tau-A did not improve the risk prediction of dementia or AD
within a 5-year and 10-year prediction horizon. Using a 5-year prediction horizon, Tau-C
improved the prediction for both dementia and AD minimally, with an AUC change of 0.01
and 0.02, respectively (p = 0.05 for both), although only with model 2 as the reference model.
In the 10-year prediction horizon Tau-C did not improve the prediction as compared to any
of the reference models. A combined model including both Tau-A and Tau-C did not improve
their predictive capacity.
Table 2. Association of Tau-A and Tau-C with the risk of incident dementia and Alzheimer’s disease.
Continuous
(per log SD decrease)
Dichotomized at median Quartiles
> (Ref: <) Q1 Q2 Q3 Q4
Biomarker Outcome HR 95% CI P HR 95% CI P HR HR 95% CI P HR 95% CI P HR 95% CI P
M1 Tau-A Dementia 0.87 0.79–0.96 0.005 0.81 0.67–0.98 0.03 Ref 0.94 0.72–1.22 0.6 0.83 0.63–1.09 0.2 0.74 0.57–0.98 0.03
AD 0.83 0.72–0.96 0.01 0.68 0.50–0.91 0.01 Ref 0.82 0.56–1.20 0.3 0.63 0.41–0.95 0.03 0.61 0.40–0.91 0.02
Tau-C Dementia 0.88 0.80–0.96 0.005 0.79 0.67–0.94 0.007 Ref 0.89 0.71–1.11 0.3 0.80 0.64–1.01 0.06 0.71 0.55–0.91 0.006
AD 0.83 0.72–0.95 0.009 0.71 0.55–0.93 0.01 Ref 0.84 0.60–1.18 0.3 0.66 0.46–0.94 0.02 0.66 0.46–0.96 0.03
M2 Tau-A Dementia 0.87 0.79–0.96 0.004 0.81 0.67–0.98 0.03 Ref 0.94 0.72–1.22 0.6 0.83 0.63–1.09 0.2 0.74 0.57–0.98 0.03
AD 0.83 0.72–0.96 0.01 0.68 0.50–0.91 0.01 Ref 0.82 0.56–1.21 0.3 0.63 0.41–0.95 0.03 0.61 0.40–0.91 0.02
Tau-C Dementia 0.88 0.80–0.96 0.006 0.79 0.67–0.94 0.008 Ref 0.89 0.71–1.12 0.3 0.81 0.64–1.02 0.07 0.71 0.56–0.91 0.008
AD 0.83 0.72–0.95 0.008 0.71 0.55–0.93 0.01 Ref 0.84 0.60–1.17 0.3 0.66 0.46–0.94 0.02 0.66 0.46–0.96 0.03
M3 Tau-A Dementia 0.89 0.81–0.99 0.03 0.85 0.70–1.04 0.1 Ref 0.98 0.75–1.28 0.9 0.88 0.66–1.16 0.4 0.79 0.59–1.06 0.1
AD 0.87 0.74–1.01 0.07 0.71 0.52–0.98 0.03 Ref 0.89 0.60–1.32 0.6 0.67 0.44–1.04 0.07 0.67 0.43–1.04 0.07
Tau-C Dementia 0.90 0.82–0.99 0.03 0.84 0.70–1.00 0.05 Ref 0.89 0.71–1.12 0.3 0.84 0.66–1.06 0.1 0.76 0.58–0.98 0.03
AD 0.87 0.75–1.00 0.05 0.78 0.60–1.03 0.08 Ref 0.87 0.62–1.23 0.4 0.72 0.50–1.05 0.09 0.75 0.51–1.11 0.1
Ref: reference group. M1: Model 1. This model was adjusted for age. M2: Model 2. This model was adjusted for age and education. M3: Model 3. This model was
adjusted for: age, education level, body mass index, smoking (never, past or current), alcohol consumption (never, <10.5 alcohol units/week, 10.5–21 alcohol units/week
or >21 alcohol units/week), physical activity (other than walking) (never, once weekly, twice weekly or three or more times per week) platelet count, white blood cell
count, albumin (mmol/L), alkaline phosphatase (unit/L), gamma glutamyltransferase (unit/L), high-density lipoprotein (mmol/L). P0.05 are marked with bold.
https://doi.org/10.1371/journal.pone.0194802.t002
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Discussion
In this study, we assessed the prognostic utility of two novel serum biomarker candidates of
neurodegeneration in a large prospective study. Both biomarkers, Tau-C in particular, were
associated with incident dementia, where high levels of the biomarkers were associated with
lower risk of incident dementia and AD.
The inverse association between levels of tau and risk of dementia seems counterintuitive
since higher levels of tau are found in the CSF of subjects with AD and to a lesser degree in
other types of dementia[17–19]. Sparks and colleagues, however, also found lower levels of tau
in plasma of AD patients and explain their association with a reduced transport of excess cen-
tral tau to the periphery, caused by pathological alterations of tau[20]. Likewise, a similar situa-
tion has been observed with the Glial Cell-Line Derived Neurotrophic Factor protein in AD
subjects. Here, the protein level is decreased in serum and increased in CSF in AD versus
Fig 1. Cumulative incidence curves. Cumulative incidence in quartiles of Tau-A and Tau-C as a function of follow-up time. Left panel
(A-C) illustrates the cumulative incidence for all-cause dementia. Right panel (D-F) illustrates the cumulative incidence for AD. The
bottom graphs (C and F) are overlay plots of Tau-A and Tau-C showing only Q1 and Q4 for both markers. Confidence intervals (95%)
are shown for the lowest (Q1) and highest quartiles (Q4) in A, B, D and E.
https://doi.org/10.1371/journal.pone.0194802.g001
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control subjects. The authors speculate that it could be related to an altered function of the
blood-brain barrier thus disturbing clearance or facilitating crossing of potentially harmful
fragments in the healthy brain[21]. Another plausible explanation is linked to neuroinflamma-
tion where microglia exhibit significant phenotypic changes during the course of the disease.
In early AD microglial activation is believed to be neuroprotective by enhancing phagocytosis
and degradation of β-amyloid and tau[22,23], a process that may result in less release of tau to
the periphery. In later stages, where microglia become over-activated, they lose their phago-
cytic abilities resulting in uncontrolled inflammation[24]. This would result in higher levels of
both central and peripheral tau.
There are previous reports of measurements of tau protein in circulating blood, but most
studies are small in size, low in numbers, and show inconsistent results[20,25–31]. A recent
meta-analysis has therefore concluded that plasma tau is not a useful marker for AD[32]. The
meta-analysis included six studies, whereof some reported an increase[26,28,29], others a
decrease[20,25] and one study reported no change in AD patients as compared to healthy age-
matched controls[27]. The heterogeneity across the studies illustrates one of the challenges of
biomarker assessment in blood. An important difference between the previous studies and
ours is that previous studies measured total tau and not truncated tau. Truncated tau appears
to be specifically related to disease pathology and recent studies have shown the presence and
Table 3. Improvement in risk prediction with the addition of Tau-A, Tau-C or Tau-A and Tau-C.
Model 2:
Age + Education
Model 3:
Multivariate
Prediction horizon Outcome Model AUC (95% CI) P AUC (95% CI) P
within 5 years Dementia Reference 0.77 (0.72–0.82) 0.79 (0.74–0.84)
+ Tau-A 0.77 (0.73–0.82) 0.9 0.79 (0.74–0.84) 0.7
Reference 0.76 (0.72–0.80) 0.78 (0.74–0.82)
+ Tau-C 0.77 (0.72–0.81) 0.05 0.78 (0.74–0.83) 0.2
Reference 0.77 (0.72–0.82) 0.79 (0.74–0.84)
+ Tau-A +Tau-C 0.78 (0.73–0.83) 0.2 0.79 (0.74–0.84) 0.9
AD Reference 0.80 (0.73–0.86) 0.82 (0.75–0.89)
+ Tau-A 0.79 (0.72–0.85) 0.4 0.81 (0.73–0.88) 0.3
Reference 0.78 (0.71–0.84) 0.82 (0.75–0.89)
+ Tau-C 0.80 (0.74–0.86) 0.05 0.83 (0.76–0.89) 0.2
Reference 0.80 (0.73–0.86) 0.82 (0.75–0.89)
+ Tau-A +Tau-C 0.80 (0.74–0.87) 0.6 0.82 (0.75–0.89) 0.96
within 10 years Dementia Reference 0.77 (0.74–0.80) 0.77 (0.75–0.80)
+ Tau-A 0.77 (0.74–0.80) 0.4 0.78 (0.75–0.80) 0.6
Reference 0.76 (0.74–0.79) 0.77 (0.74–0.79)
+ Tau-C 0.76 (0.74–0.79) 0.7 0.77 (0.74–0.79) 0.97
Reference 0.77 (0.74–0.80) 0.77 (0.75–0.80)
+ Tau-A +Tau-C 0.77 (0.74–0.80) 0.5 0.78 (0.75–0.80) 0.6
AD Reference 0.76 (0.72–0.80) 0.77 (0.73–0.81)
+ Tau-A 0.77 (0.73–0.80) 0.5 0.78 (0.74–0.81) 0.6
Reference 0.74 (0.71–0.77) 0.75 (0.72–0.79)
+ Tau-C 0.75 (0.72–0.78) 0.1 0.76 (0.72–0.79) 0.3
Reference 0.76 (0.72–0.80) 0.77 (0.73–0.81)
+ Tau-A +Tau-C 0.77 (0.73–0.81) 0.2 0.78 (0.74–0.82) 0.3
Compared with reference model, P0.05 are marked with bold
https://doi.org/10.1371/journal.pone.0194802.t003
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elevation of several truncated tau species in CSF of AD patients[33]. Besides being more spe-
cific for pathological changes than the intact proteins, the truncated fragments might more
easily pass through the blood-brain barrier, due to their smaller size, as larger fragments do
not cross the barrier.
Another important difference is the setting in which the markers are assessed. With one
exception[31], the previous studies of plasma tau are cross-sectional, while ours is longitudinal,
and thereby the first large cohort study to assess the prognostic utility of truncated tau in
serum. Importantly the longitudinal design limit the concern of reverse causation. Mattson
and colleagues recently touched upon the prognostic potential of plasma tau where they found
that higher plasma tau was associated with progression, measured as the change in cognitive
performance over time, however this was assessed in subjects with MCI and established
dementia and not cognitively normal individuals [31]. The biomarker dynamics of Tau-A and
Tau-C as a function of disease severity are still to be elucidated, but based on the current obser-
vations we speculate that the levels of the biomarkers are time-dependent and may change
direction during the course of the disease. In minor cross-sectional studies of dementia and
mild traumatic brain injury subjects, we found that the levels of Tau-A and Tau-C were ele-
vated in diseased versus control subjects[9,10]. Associations with opposite direction as to what
we found in this prognostic analysis. While the influence on the disease path after processing
of tau by ADAM10 is unknown, evidence suggests that the caspase cleavage leading to the gen-
eration of Tau-C may play an important role in the cascade leading to tau aggregation[34].
The Tau-C fragment has been found to be one of the truncated tau forms in NFTs[8]. This evi-
dence suggests that Tau-C may accumulate within the neurons during the process of NFT for-
mation, and eventually be released to the circulation, at a more advanced disease stage, where
the NFT load is sufficient to cause neuronal cell death. This process could explain the associa-
tions we have observed in our cross-sectional and longitudinal studies, respectively. There are
previous indications of a non-linear relation between tau and disease severity over time. Using
data from the ADNI database, Mouiha and colleagues investigated the time course of the CSF
biomarkers, Aβ, t-tau and p-tau, and for all three markers the most likely model describing the
relation between the biomarkers and disease severity was non-linear[35]. The most likely time
course for t-tau and p-tau was found to be a penalized B-spline model, where multiple inflex-
ion points could indicate multiple phases of accumulation as opposed to a continuous, unin-
terrupted process. Recent longitudinal data from the DIAN study also suggest that the
biomarker trajectories may differ as a function of disease severity[36].
While the associations of Tau-C and Tau-A with incident dementia and AD revealed a
potential value of these novel biomarker candidates, their predictive value as individual mark-
ers was limited. Tau-C gave a very modest increase in the AUC in a 5-year prediction horizon
as compared to a reference model based on age and education, however the increase in AUC
vanished in the fully adjusted model. It must be noted that this assessment was done in a popu-
lation-based cohort without any specific enrichment e.g. a requirement for Aβ positivity. The
heterogeneous population may leach out the predictive performance. Despite the limited pre-
dictive value as stand-alone biomarkers, it is likely that the markers could be useful in combi-
nation with other serum biomarkers e.g. other tau-species and β-amyloid. From our study it is
clear that the interpretation of a peripheral signal and its relation to alterations within the
brain is difficult, albeit studies, including the current study, begin to highlight that serological
assessment of pathophysiological tau processing is possible. Understanding the link between
the biomarker signal and the pathophysiological processes is however of paramount impor-
tance and studies that can reveal the time-dependency and biomarker dynamics in relation to
disease severity e.g. with repeated measures should therefore be a priority for the future.
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A peripheral biomarker of biologically processed tau has several advantages as compared to
β-amyloid. First, while the Amyloid Precursor protein is also expressed in peripheral tissues
like the pancreas, kidney, heart and liver[37], animal studies suggest that circulating tau pro-
tein arises from central neurons[38]. This implies that the peripheral pool of tau would arise
directly from the brain, while β-amyloid in plasma or serum probably reflects a mixture of
peripheral and brain-derived protein. This might make the interpretation of a peripheral tau
signal easier, although the processing, release and transport of tau from the brain to the periph-
ery is yet not fully understood. Similar to a previous study of total tau measured in plasma, our
markers did not show any correlation with t-tau or p-tau levels in CSF suggesting that the
steady-state concentrations of tau are differentially regulated in these two body fluids[10,26].
Secondly, it has become quite clear that, although CSF Aβ aids in the early diagnosis of AD,
the marker is not related to disease severity and duration[39,40]. CSF Tau, on the other hand,
correlates with disease severity during the whole time course of AD[40–42]. An association
that is also likely with truncated tau in the periphery. Finally, tau outperformed Aβ in a head-
to-head comparison from a recent meta-analysis, where tau proved to have a larger effect size
(measured by the disease to control ratio) in both CSF and plasma/serum[43].
Limitations
Generally the dementia field is hampered by misdiagnosis and underdiagnoses which compli-
cate the evaluation of new diagnostic and prognostic biomarkers. In the current study we used
registry-linkage to collect information on dementia diagnoses. This method has the advantage
of a very limited loss to follow up, however one could question the validity of the diagnoses
due to its origin, and access to specific information regarding this cannot be obtained. Similar
registries are found in other countries in Scandinavia, and studies from Sweden and Finland
have shown that the diagnoses in the registries have very good accuracy, but underestimation
is present. This underestimation may result in an underestimation of the biomarker potential.
[44,45]
Like most other studies we based our biomarker assessment on a binary distinction between
cases and controls. Since dementia evolves over decades with a long preclinical phase the
binary distinction is probably not the most appropriate method as the control group may con-
tain several subjects with preclinical disease at the time of biomarker assessment. Although
this is difficult to work around, a long follow-up time as in the current study, is one of the best
possibilities to avoid misclassifications.
In literature, variability in assays and detection challenges are reported as two major hurdles
with peripheral biomarkers that should be overcome before the full potential of these biomark-
ers is expressed[46,47]. At least for our Tau-A assay we also faced a challenge with sensitivity,
which we hope to overcome with assay optimization. In a sensitivity analysis, we did not
observed any significant impact on the overall findings of the samples measured below the
LLOQ with intra-assay CVs above 15%. The current study was limited to women and therefore
generalization cannot be made to men of same age. The biomarker candidates should be tested
in other cohorts to ensure reproducibility and generalizability.
Finally, tau pathology is not specific to AD, but present in multiple dementias[5], a finding
the corresponds to our findings which are consistent across dementia forms.
Conclusions
The current study demonstrates that serological assessment of pathophysiological tau process-
ing is possible. Tau-A and Tau-C measured in serum could be useful prognostic biomarkers to
aid in early diagnosis of preclinical dementia and AD. Additional validation in relation to
Serum biomarker candidates are associated with dementia
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prognosis and time-dependency of these novel biomarkers should be a subject for future
investigations.
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